Current treatment guidelines recommend IV thrombolytic therapy, such as recombinant tissue plasminogen activator (tPA) or tenecteplase (TNK), for ischemic stroke presenting within 4.5 h of symptom onset or endovascular thrombectomy to those not eligible or presenting beyond 4.5 h of symptom onset. This evidence concerns the gene PLAT and ischemic stroke.